The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations

The present retrospective study was conducted to evaluate the efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring driver mutations. Patients with NSCLC harboring driver mutations who received ICIs (nivolumab or pembrolizumab) were re...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Clin Oncol
Autori principali: Sakamoto, Hiroaki, Tanaka, Hisashi, Shiratori, Toshihiro, Baba, Keisuke, Ishioka, Yoshiko, Itoga, Masamichi, Taima, Kageaki, Hasegawa, Yukihiro, Takanashi, Shingo, Tasaka, Sadatomo
Natura: Artigo
Lingua:Inglês
Pubblicazione: D.A. Spandidos 2019
Soggetti:
Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6482391/
https://ncbi.nlm.nih.gov/pubmed/31031976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2019.1838
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi